Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/17502
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Antiemetics in children receiving chemotherapy |
Author: | Roila, F. Feyer, P. Maranzano, E. Olver, I. Clark-Snow, R. Warr, D. Molassiotis, A. |
Citation: | Supportive Care in Cancer, 2005; 13(2):129-131 |
Publisher: | Springer-Verlag |
Issue Date: | 2005 |
ISSN: | 0941-4355 1433-7339 |
Abstract: | Only a few studies have been carried out in children on the prevention of chemotherapy-induced acute emesis. 5-HT3 antagonists have been shown to be more efficacious and less toxic than metoclopramide, phenothiazines and cannabinoids. The optimal dose and scheduling of the 5-HT3 antagonists has not been identified. Combinations of a 5-HT3 antagonist and dexamethasone show increased efficacy with respect to 5-HT3 antagonists alone. All pediatric patients receiving chemotherapy of high or moderate emetogenic potential should receive a combination of a 5-HT3 antagonist and dexamethasone to prevent acute emesis. No studies have specifically evaluated antiemetic drugs in the prevention of chemotherapy-induced delayed and anticipatory emesis in children. |
Keywords: | Humans Vomiting Dexamethasone Antiemetics Antineoplastic Agents Drug Therapy, Combination Child Randomized Controlled Trials as Topic Practice Guidelines as Topic Serotonin 5-HT3 Receptor Antagonists |
DOI: | 10.1007/s00520-004-0702-6 |
Published version: | http://dx.doi.org/10.1007/s00520-004-0702-6 |
Appears in Collections: | Aurora harvest 6 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.